

## Supplementary material

### Immunity after COVID-19 and vaccination: follow-up study over one year among medical personnel

Vivian Glück<sup>1</sup>, Sonja Grobecker<sup>1</sup>, Josef Köstler<sup>1</sup>, Leonid Tydykov<sup>1</sup>, Manuela Bertok<sup>2</sup>, Tanja Weidlich<sup>2</sup>, Christine Gottwald<sup>2</sup>, Bernd Salzberger<sup>3</sup>, Ralf Wagner<sup>1,4</sup>, Florian Zeman<sup>5</sup>, Michael Koller<sup>5</sup>, André Gessner<sup>1,4</sup>, Barbara Schmidt<sup>1,4</sup>, Thomas Glück<sup>2</sup>, David Peterhoff<sup>1,4\*</sup>

<sup>1</sup> Institute for Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany


<sup>2</sup> Kliniken Südostbayern AG, Klinikum Traunstein, Traunstein, Germany

<sup>3</sup> Department for Infection Control and Infectious Diseases, University Hospital Regensburg, Regensburg, Germany

<sup>4</sup> Institute for Medical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany

<sup>5</sup> Center for Clinical Studies, University Hospital Regensburg, Regensburg, Germany

\* Correspondence: [david.peterhoff@ur.de](mailto:david.peterhoff@ur.de)



**b**

visit #	presence/absence at visit										total count participants	
M0	■	■	■	■	■	■	■	■	■	■	■	136
M3	■	■	■	■	■	■	■	■	■	■	■	95
M6	■	■	■	■	■	■	■	■	■	■	■	123
M12	■	■	■	■	■	■	■	■	■	■	■	98
I+V1	■	■	■	■	■	■	■	■	■	■	■	56
count	32	30	12	19	9	9	8	3	9	4	1	

present at visit  
 absent at visit

**Fig. S1: Sampling protocol and number of participants at each time point.** (a) Sampling timelines and sampling material for the COVID-19 convalescent group (“Infection”), control group of SARS-CoV-2 naïve vaccinees (“Vaccination”) and control group of SARS-CoV-2 naïve subjects (“Naïve control”), respectively. (b) Table summarizing the counts of the combination of presences during the five study visits of the COVID-19 convalescent group. M0: sample 3 weeks (median) after onset of symptoms; M3: sample 12 weeks (median) after onset of symptoms; M6: sample 30 weeks (median) after onset of symptoms; M12: sample 48 weeks (median) after onset of symptoms; I+V1: sample 42 (median) days after vaccination; V1: sample before first vaccination; V2: sample before second vaccination; V3: sample 15 days (median) after second vaccination.